April 18 Product: Genentechs Alecensa Indication: Non-small cell lung cancer The FDA approved Genentechs Alecensa Thursday as the first adjuvant treatment for patients with early-stage, anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer who have undergone tumor resection
Good handling of these effects is crucial for securing improved health outcomes and continued treatment
It is not approved by the FDA, EMA, or any regulatory authority for human therapeutic use, diagnosis, treatment, or supplementation
Comprehensive protocols are critical for clients safety and effective treatment outcomes
The voltage of a battery pack is essentially going to determine how fast your vehicle is going to go
Abdominal fat, which is the most dangerous type metabolically, shows the most dramatic reduction